Our News

Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute
Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics

PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases